

# Oxygenta Pharmaceutical Limited

(Formerly Known as S.S.Organics Limited)

(CIN: L24110TG1990PLC012038)

To

Date: 20<sup>th</sup> May, 2022

The Corporate Relations Department,  
BSE Limited, Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai-400001.

Dear Sir(s),

**Sub: Submission of Audited Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2022**  
**Ref: Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

**Scrip Code: 524636 | Scrip Symbol: SSORGS**

\*\*\*\*\*

The Board at its meeting held today, i.e. Friday, 20<sup>th</sup> May, 2021, transacted inter-alia, the following businesses:

1. Financial Results:

The Board approved the Audited Financial Results for the fourth quarter and year ended 31<sup>st</sup> March, 2022. In this regard please find the enclosed:

- Audited Financial Results of the Company for the quarter and year ended 31<sup>st</sup> March, 2022
- Auditor's report in respect of the Audited Financial Results of the Company for the fourth quarter and year ended 31<sup>st</sup> March, 2022
- Declaration pursuant to Regulation 33(3)(d) of Listing Regulations in terms of the audit reports with unmodified opinion.

2. Appointment of Company Secretaries as Secretarial Auditors of the Company for the financial year 2022-23.

3. Appointment of Chartered Accountants as Internal Auditors of the Company for the financial year 2022-23.

The meeting of Board of Directors of the Company commenced at 03:00 P.M and concluded at 04:15 P.M.

The above information is also being made available at website of the Company <http://oxygentapharma.com>

This is for your information and records.

Thanking you

**For OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly known as S.S. ORGANICS LIMITED)

*V. Sai Sudhakar*  
**VANKINENI SAI SUDHAKAR**  
Managing Director  
DIN: 00733001



(An ISO 9001 : 2008, ISO 14001:2004 & OHSAS 18001:2007 Certified Company)

CORP.OFFICE : Plot No.43, Sy No.55 to 58, The Park View, 1st Floor, Behind Preston Prime Mall, Lumbini Avenue, Gachibowli, Hyderabad - 500 032.

Ph No: 040-23353690, Email id : [cs@ssorganics.co.in](mailto:cs@ssorganics.co.in)

REGD.OFF & FACTORY : Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist) - 502 291.T.S. India. Tel : (08455) 250080 / 25080, Fax : 08455-250090

CIN : L24110TG1990PLC012038. E-mail: [info@ssorganics.co.in](mailto:info@ssorganics.co.in) Website : [www.ssorganics.co.in](http://www.ssorganics.co.in)



**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly known as S. S. ORGANICS LIMITED )

CIN:L24110TG1990PLC012038

Regd Office: Survey No. 252/1, Aroor Village, Sadasivapet Mandal, Sangareddy Dist, Telangana State

Website: www.ssorganics.co.in, Email lds: md@ssorganics.co.in, cs@ssorganics.co.in, Phone Number: 040- 23355938


**STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31 ST MARCH 2022**

(Rupees in Lakhs except for EPS)

S. No	Particulars	Quarter Ended 31-March-2022 (Audited)	Quarter Ended 31-December-2021 (Un-Audited)	Quarter Ended 31-March-2021 (Audited)	Year ended 31-Mar-2022 (Audited)	Year ended 31-Mar-2021 (Audited)
1	<b>Income</b>					
	(a) Revenue from Operations	707.56	1,593.07	1,109.24	6,052.48	5,202.70
	(b) Other Income	0.32	0.03	6.80	0.45	9.12
	<b>Total income</b>	<b>707.89</b>	<b>1,593.10</b>	<b>1,116.04</b>	<b>6,052.94</b>	<b>5,211.82</b>
2	<b>Expenses</b>					
	(a) Cost of materials consumed	468.09	980.77	1,014.03	4,267.42	4,301.71
	(b) Purchase of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	57.52	234.27	(343.91)	454.71	(638.68)
	(d) Direct Manufacturing Expenses	236.43	238.95	278.51	946.00	934.29
	(e) Employee benefit expense	7.92	6.77	22.00	33.04	55.37
	(f) Finance Costs	16.43	21.97	132.49	92.49	178.28
	(g) Depreciation and amortisation expense	38.23	40.30	42.88	159.13	119.59
	(g) Other expenses	81.01	48.27	86.70	203.71	167.55
	<b>Total expenses</b>	<b>905.64</b>	<b>1,571.30</b>	<b>1,232.70</b>	<b>6,156.51</b>	<b>5,118.11</b>
3	<b>Profit from operations before other income and exceptional items (1-2)</b>	<b>(197.75)</b>	<b>21.80</b>	<b>(116.66)</b>	<b>(103.57)</b>	<b>93.70</b>
4	<b>Other income</b>	-	-	-	-	-
5	<b>Profit from ordinary activities before exceptional items (3+4)</b>	<b>(197.75)</b>	<b>21.80</b>	<b>(116.66)</b>	<b>(103.57)</b>	<b>93.70</b>
6	<b>Exceptional (expenses)/income</b>	<b>118.43</b>	<b>-</b>	<b>218.89</b>	<b>54.64</b>	<b>218.89</b>
7	<b>Profit / (Loss) from ordinary activities before tax (7+ 8)</b>	<b>(79.33)</b>	<b>21.80</b>	<b>102.23</b>	<b>(48.94)</b>	<b>312.59</b>
8	<b>Tax (Credit) Deferred Tax</b>	<b>12.11</b>	<b>-</b>	<b>21.39</b>	<b>12.11</b>	<b>21.39</b>
9	<b>Net Profit / (Loss) from ordinary activities after tax</b>	<b>(91.44)</b>	<b>21.80</b>	<b>80.84</b>	<b>(61.05)</b>	<b>292.99</b>
10	<b>Extraordinary items (net of tax expense )</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
11	<b>Net Profit / (Loss) for the period (11+ 12)</b>	<b>(91.44)</b>	<b>21.80</b>	<b>80.84</b>	<b>(61.05)</b>	<b>292.99</b>
12	<b>Other Comprehensive Income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
13	<b>Total Comprehensive Income</b>	<b>(91.44)</b>	<b>21.80</b>	<b>80.84</b>	<b>(61.05)</b>	<b>292.99</b>
14	Share of Profit/(loss) of associates		-			
15	Minority Interest		-			
16	<b>Paid-up equity share capital</b> (face value Rs. 10/- )	<b>1,420.13</b>	<b>1,420.13</b>	<b>1,020.13</b>	<b>1,420.13</b>	<b>1,020.13</b>
17.i	<b>Earnings per share (before extraordinary items)</b> ( of Rs.10/- each ) (not annualised):					
	(a) Basic	(0.64)	0.15	0.79	(0.48)	2.87
	(b) Diluted	(0.64)	0.15	0.79	(0.48)	2.87
17.ii	<b>Earnings per share (after extraordinary items)</b> ( of Rs.10/- each ) (not annualised):					
	(a) Basic	(0.64)	0.15	0.79	(0.48)	2.87
	(b) Diluted	(0.64)	0.15	0.79	(0.48)	2.87

**Notes**

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 20 May 2022 at Plot N0.43, Sy N0.55 to 58, The Park View, 1st Floor, Behind Preston Prime Mall, Lumbini Avenue, Gachibowli, Hyderabad - 500 032.
- The Company operates in a single segment and the results pertain to a single segment.
- Revenue from Operations also includes Job Work Income.
- Previous period/year figures have been regrouped and rearranged wherever considered necessary.
- Exceptional Items includes long outstanding credit and debit balances written off which are no longer payable.
- The Standalone Financial Results are reviewed by the Statutory auditors of the company as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015



For OXYGENTA PHARMACEUTICAL LIMITED  
(Formerly known as S. S. ORGANICS LIMITED )

*V. Sai Sudhakar*

SAI SUDHAKAR VANKINENI  
Managing Director  
DIN:00733001

Place: Hyderabad  
Date: 20-05-2022



**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)

Balance Sheet as at 31 March 2022

	Note	As at 31 March 2022	As at 31 March 2021
<b>Assets</b>			
<b>Non-current assets</b>			
Property, plant and equipment	4(a)	19,97,71,081	16,31,09,819
Capital work-in-progress		34,31,026	65,49,629
Intangible assets	4(b)		
Financial assets			
Investments	5	4,93,900	4,93,900
Loans	6	41,97,000	34,63,000
Trade Receivables	7	66,94,275	21,91,011
Others	8	45,52,316	34,02,316
Other non current assets			
Deferred tax assets, net			
		<b>21,91,39,598</b>	<b>17,92,09,675</b>
<b>Current assets</b>			
Inventories	9	7,28,31,038	12,11,37,297
Financial assets			
Trade receivables	10	1,27,45,909	1,61,03,464
Cash and cash equivalents	11	15,56,803	44,50,259
Other bank balances	12	-	-
Loans	13	-	3,87,415
Others	14	44,92,117	37,60,325
Balances with Revenue/Tax Authorities	15	9,97,532	1,35,98,106
Other current assets	16	-	-
		<b>9,26,23,398</b>	<b>15,94,36,866</b>
<b>Total assets</b>		<b>31,17,62,995</b>	<b>33,86,46,541</b>
<b>Equity and Liabilities</b>			
<b>Equity</b>			
Equity share capital	17	14,20,13,000	10,20,13,000
Other equity	18	(48,83,03,669)	(48,21,99,029)
<b>Total equity</b>		<b>(34,62,90,669)</b>	<b>(38,01,86,029)</b>
<b>Non-current liabilities</b>			
Financial Liabilities			
Borrowings	19	51,04,28,555	45,03,75,848
Trade payables	20	3,98,05,941	5,34,66,843
Other non-current liabilities	21	2,52,60,149	2,66,22,730
Deferred Tax Liabilities		1,46,11,103	1,34,00,069
		<b>59,01,05,747</b>	<b>54,38,65,491</b>
<b>Current liabilities</b>			
Financial Liabilities			
Loans	22	1,08,59,549	2,84,95,921
Trade payables	23	5,21,22,593	13,78,91,605
Other financial liabilities	24	-	-
Other current liabilities	25	37,92,908	77,06,835
Provisions	26	11,72,866	8,72,718
Current tax liabilities			
		<b>6,79,47,916</b>	<b>17,49,67,079</b>
<b>Total liabilities</b>		<b>65,80,53,663</b>	<b>71,88,32,569</b>
<b>Total equity and liabilities</b>		<b>31,17,62,996</b>	<b>33,86,46,541</b>
Notes forming part of standalone financial statements			

for and on behalf of the Board of Directors of  
**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)  
CIN: L24110TG1990PLC012038



*V. Sai Sudhakar*

**SAI SUDHAKAR VANKINENI**  
Managing Director  
DIN:00733001

Place: Hyderabad  
Date: 20-05-2022



**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)  
Cash Flow Statement for the year ended March 31, 2022

	For the year ended 31 March 2022	For the year ended 31 March 2021
<b>I. Cash flows from operating activities</b>		
Profit before tax	(48,93,606)	3,14,38,053
Adjustments to reconcile profit before tax to net cash flows:		
Depreciation of tangible assets	1,59,13,247	1,19,59,369
Amorisation of intangible assets	-	-
Finance income (including fair value change in financial instruments)	(44,899)	(2,25,290)
Dividend income from mutual funds	-	-
Finance costs (including fair value change in financial instruments)	92,49,406	1,78,28,421
Re-measurement losses on defined benefit plans	-	-
<b>Operating profit before working capital changes</b>	<b>2,02,24,148</b>	<b>6,10,00,553</b>
Changes in working capital:		
Adjustment for (increase)/decrease in operating assets		
Trade receivables - Non current	(45,03,264)	(21,91,011)
Trade receivables - current	33,57,556	(1,18,66,523)
Inventories	4,83,06,259	(7,86,06,283)
Loans - Non current	(7,34,000)	2,19,580
Loans - current	3,87,415	43,91,030
Other financial assets - current	-	-
Other assets - current	1,18,68,782	(23,74,024)
Other assets - non current	(11,50,000)	(32,88,250)
Adjustment for (increase)/decrease in operating liabilities		
Trade payables	(10,34,05,384)	8,03,96,802
Other financial liabilities - current	(36,13,778)	(6,39,01,158)
Other current liabilities		
Provisions - Non Current	12,11,034	21,39,535
<b>Cash generated from operations</b>	<b>(2,80,51,233)</b>	<b>(1,40,79,748)</b>
Interest Paid	-	-
Deferred Taxes/ Income taxes paid/charged	(12,11,034)	(21,39,535)
<b>Net cash generated from/(used in) operating activities</b>	<b>(2,92,62,267)</b>	<b>(1,62,19,283)</b>
<b>II. Cash flows from investing activities</b>		
Purchase of property, plant and equipment and intangibles (including capital work in progress)	(4,94,55,905)	(6,74,12,254)
(Investments in)/ redemption of bank deposits (having original maturity of more than three months) - net		
Dividend received on mutual funds	44,899	2,25,290
Interest received (finance income)		
<b>Net cash used in investing activities</b>	<b>(4,94,11,006)</b>	<b>(6,71,86,964)</b>
<b>III. Cash flows from financing activities</b>		
Proceeds from Share Capital	4,00,00,000	-
Proceeds from/(repayment of) long-term borrowings, net	4,50,29,223	10,45,01,717
Interest paid	(92,49,406)	(1,78,28,421)
<b>Net cash provided by financing activities</b>	<b>7,57,79,817</b>	<b>8,66,73,296</b>
<b>Net increase in cash and cash equivalents (I+II+III)</b>	<b>(28,93,456)</b>	<b>32,67,048</b>
Cash and cash equivalents at the beginning of the year	44,50,259	11,83,211
<b>Cash and cash equivalents at the end of the year (refer note below)</b>	<b>15,56,803</b>	<b>44,50,259</b>
<b>Note:</b>		
Cash and cash equivalents comprise:		
Cash on hand	3,74,239	97,922
Balances with banks:		
- in current accounts & Deposits	11,82,564	43,52,337
	<b>15,56,803</b>	<b>44,50,259</b>
Notes forming part of standalone financial statements	1-44	



for and on behalf of the Board of Directors of  
**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly Known as SS Organics Limited)  
CIN: L24110TG1990PLC012038

For and on behalf of the Board of Directors:

*V. Sai Sudhakar*

**SAI SUDHAKAR VANKINENI**  
Managing Director  
DIN:00733001

Place: Hyderabad  
Date: 20-05-2022





Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To  
The Board of Directors of  
**OXYGENTA PHARMACEUTICAL LIMITED**  
(Formerly known as S. S. ORGANICS LIMITED)

Report on the Audit of Standalone Financial Results

### Opinion

We have audited the accompanying statement of quarterly and year to date standalone financial results of **OXYGENTA PHARMACEUTICAL LIMITED (Formerly known as S. S. ORGANICS LIMITED)** (hereinafter referred to as the "Company") for the quarter ended March 31, 2022 and for the year ended March 31, 2022 ("Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- (i) Is presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- (ii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 (the "Act") and other accounting principles generally accepted in India, of net Loss and other comprehensive income and other financial information of the Company for the quarter ended March 31, 2022 and for the year ended March 31, 2022.

### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SA's) specified under section 143(10) of the Act and other applicable pronouncements issued by the Institute of Chartered Accountants of India. Our responsibilities under those SA's are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



### **Management's Responsibilities for the Standalone Financial Results**

The Statement has been prepared on the basis of the standalone annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the statement that give a true and fair view of the net loss and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the statement, the Board of Directors of the Company are responsible for assessing the ability of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the Company are responsible for overseeing the Companies' financial reporting process.

### **Auditor's Responsibility for the Audit of the Standalone Financial Results**

Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.

As part of an audit in accordance with SA's, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company





has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Other Matters

The Financial Results include the results for the quarter ended March 31, 2022 being the balancing figures between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year to date figures up to the third quarter of the current financial year, which were subjected to a Limited Review by us, as required under the Listing Regulations.

Date: May 20, 2022  
Place: Hyderabad

For Gowri Shankar & Associates  
Chartered Accountants  
Firm Registration No. 015625S



*S. Gowri Shankar*

Gowri Shankar Seshapu  
Partner

M No. 234732

UDIN: 22234732AJHTTH8750